Patent Cliff Drives Pharma To China While EquitiesFirst Unlocks Capital

American pharmaceutical giants face a $236 billion revenue cliff through 2030 as blockbuster drugs lose patent protection. Humira has already fallen—its annual sales dropping from $21 billion in 2022 to under $9 billion in 2024 after biosimilars arrived. Keytruda and Eliquis, generating $25 billion and $12 billion annually, face the same fate by 2028.

"Every major pharma CEO is asking the same question: where do we find the next generation of drugs without spending billions per approval?" says Al Christy Jr., founder and CEO of specialty finance firm Equities First Holdings. "Increasingly, the answer is China."

A Biotech Boom

Some traders have already placed their bets. Hong Kong's biotech index has surged nearly 80% in 2025 and significantly outpaced the broader Hang Seng Index. Mainland Chinese investors have poured roughly $90 billion into the market. The rally reflects a fundamental shift: Chinese companies now originate one-third of global pharmaceutical licensing deals, up from single digit percentages just a decade ago. Strategic pharmaceutical investment specialists have recognized the significance of this market transformation.

"The 80% rally in Hong Kong biotech speaks for itself," says Christy. "The challenge isn't finding enthusiasm and momentum. It's how to deploy capital efficiently when valuations are moving this fast."

Chinese companies claimed 18% of all global licensing deals in the first half of 2025, their largest share on record, and accounted for one-third of total deal value. Hong Kong has reclaimed the top spot for global IPO proceeds, aided by a pipeline of healthcare listings and the surge in mainland investment.

Inside Drug Development in China

What transformed the Chinese biotech market? The answer may lie in somewhat of an accidental policy success. When Beijing slashed generic drug prices to control healthcare costs, it inadvertently forced companies to innovate or perish. Survivors emerged battle-tested and hungry. Investment advisory platforms have noted how this policy-driven transformation reshaped the competitive landscape.

Today, Chinese firms can develop drugs at costs 30-60% lower than in the United States, according to industry analyses. Patient recruitment runs 2-3 times faster, leveraging centralized hospital systems and 1.4 billion potential patients. China's regulatory approvals now take just 60 working days—soon to be cut to 30—matching FDA timelines. At this year's premier cancer conference, Chinese companies presented one-third of all drug candidates.

The Pfizer Playbook

Pfizer's recent $6 billion deal with China's 3SBio could offer a template for what's coming. The U.S. giant paid $1.25 billion upfront for a cancer drug, but crucially, plans to manufacture it in America, sidestepping potential tariffs while accessing Chinese innovation.

This hybrid model—Chinese discovery, Western commercialization—could be a workaround of regulatory hurdles and geopolitical risks while capturing innovation arbitrage. Global biotech capital solutions have become increasingly important as companies navigate these complex cross-border partnerships.

The FDA has issued draft guidance on this approach, emphasizing that companies run multi-country trials rather than China-only studies. That's forcing Chinese firms to meet global standards, which ultimately could make them stronger competitors.

Risks

Despite the enthusiasm, some uncomfortable facts lurk beneath the surface. Of 63 Chinese biotechs that went public in Hong Kong between 2018 and 2023, only nine traded above their IPO price in 2024. Companies can remain unprofitable, burning cash while chasing drug approvals.

Trade tensions add another wildcard. Washington has floated pharmaceutical tariffs up to 200%, though none have materialized yet. But the threat alone could reshape deal structures, pushing companies toward U.S. manufacturing and dual-supply chains.

The Next Five Years

Chinese biotech could be where Japanese autos were in the 1970s: dismissed by incumbents, but rapidly improving and cost-competitive. The difference is speed. Drug development moves faster than automotive cycles, and patent cliffs create immediate demand for solutions.

For those who believe this rally has legs, flexibility could be key. Christy Jr.'s alternative equity-backed financing solutions offer access to liquid capital financed against existing equity positions, which could allow for taking new positions on Chinese biotech while maintaining longer-term outlooks.

For Western pharma more broadly, the calculation is simple: partner with Chinese innovation or watch revenues evaporate as patents expire. For investors, it's about riding a generational shift in the geographic distribution of drug development while managing political and regulatory risks.

The smartest players aren't choosing between East and West. They're building bridges—and financing structures—that can capture the potential of both.

Disclaimer: This is a sponsored article. All possible measures have been taken to ensure accuracy, reliability, timeliness and authenticity of the information; however Outlookindia.com does not take any liability for the same. Using of any information provided in the article is solely at the viewers’ discretion.